*Result*: A systematic review and meta-analysis of the use of human albumin solution for treating the complications of liver cirrhosis.
Original Publication: [Hoboken, NJ] : Wiley Periodicals, Inc. on behalf of the American Association for the Study of Liver Diseases, [2017]-
China L, Freemantle N, Forrest E, Kallis Y, Ryder SD, Wright G, et al. A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med. 2021;384:808–817.
CDC—U.S. Centers for Disease Control and Prevention. FastStats—Chronic Liver Disease or Cirrhosis. Accessed July 9, 2025. https://www.cdc.gov/nchs/fastats/liver-disease.htm#print.
Office for Health Improvement & Disparities. Liver disease: Applying All Our Health. Accessed July 9, 2025. https://www.gov.uk/government/publications/liver-disease-applying-all-our-health/liver-disease-applying-all-our-health#fn:4.
Shrestha DB, Budhathoki P, Sedhai YR, Baniya R, Awal S, Yadav J, et al. Safety and efficacy of human serum albumin treatment in patients with cirrhotic ascites undergoing paracentesis: A systematic review and meta-analysis. Ann Hepatol. 2021;26:100547.
Leache L, Gutiérrez-Valencia M, Saiz LC, Uriz J, Bolado F, García-Erce JA, et al. Meta-analysis: Efficacy and safety of albumin in the prevention and treatment of complications in patients with cirrhosis. Aliment Pharmacol Ther. 2023;57:620–634.
Bai Z, Wang L, Wang R, Zou M, Méndez-Sánchez N, Romeiro FG, et al. Use of human albumin infusion in cirrhotic patients: A systematic review and meta-analysis of randomized controlled trials. Hepatol Int. 2022;16:1468–1483.
Sandi BB, Leao GS, de Mattos AA, de Mattos AZ. Long-term albumin administration in patients with cirrhosis and ascites: A meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2021;36:609–617.
Ashour AA, Atta MA, Sadek KW, Obaid KR, Ashour MA, Ashour A, et al. Albumin administration in patients with decompensated liver cirrhosis: A meta-analytic update. Eur J Gastroenterol Hepatol. 2021;33:479–486.
Zaccherini G, Tufoni M, Bernardi M. Albumin administration is efficacious in the management of patients with cirrhosis: A systematic review of the literature. Hepat Med. 2020;12:153–172.
Xu T, Liu W, Huang R. Can albumin reduce the mortality of patients with cirrhosis and ascites? A meta-analysis of randomized controlled trials. Eur J Gastroenterol Hepatol. 2023;35:80–88.
Kar PS, Venishetty S, Laroia ST, Jindal A, Maiwall R, Sood AK, et al. Tolerance of standard dose albumin infused over 6 hrs for treatment of spontaneous bacterial peritonitis—A randomized controlled trial. Indian J Gastroenterol. 2023;42:505–516.
O’Leary JG, Perricone G, Laleman W, Milovanovic T, Torres M, Campins N, et al. LBO-003 Efficacy and safety of long-term human albumin therapy in cirrhotic patients with acute decompensation and ascites: Topline results of the PRECIOSA trial. J Hepatol. 2025;82:S10.
Sujith Reddy JSN, Jagtap N, Kalpala R, Kulkarni A, Gupta R, Nagaraja Rao P, et al. Midodrine versus albumin to prevent paracentesis induced circulatory dysfunction in acute on chronic liver failure patients in the outpatient clinic—A randomized controlled trial. J Clin Exp Hepatol. 2023;13:576–585.
Solà E, Solé C, Simón-Talero M, Martín-Llahí M, Castellote J, Garcia-Martínez R, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. J Hepatol. 2018;69:1250–1259.
0 (Albumins)
*Further Information*
*Background: Decompensated liver cirrhosis is characterized by serious complications and high mortality. Intravenous human albumin solution (HAS) has been used for decades to treat these complications, and this systematic review aims to evaluate the clinical effectiveness and safety of HAS and compare it with alternatives.
Methods: We searched MEDLINE (Ovid), Embase (Ovid), and CENTRAL (Cochrane Central Register of Controlled Trials) for Randomized Controlled Trials (RCTs) of HAS to treat liver cirrhosis. RCTs evaluating the use of HAS in cirrhotic adults were eligible. The clinical effect of protocol-guided HAS compared with alternatives on mortality was our principal outcome. Secondary outcomes included renal dysfunction, hepatic encephalopathy, gastrointestinal bleeding, portal hypertensive bleeding, recurrence of ascites, bacterial infections, paracentesis-induced circulatory dysfunction, multiorgan failure, and acute-on-chronic liver failure. Random effect odds ratios (ORs) and their confidence intervals (CIs) were reported.
Results: Sixty-eight RCTs were included, with 4 evaluated as low risk of bias. Fifty-six RCTs reported mortality, with a statistically significant reduction in the overall odds of death compared with alternatives. The overall pooled random OR was 0.769 (95% CI 0.652-0.908), p=0.0019. Subgroup analyses grouping trials by size showed that only those with <100 participants demonstrated a significant reduction in overall odds of death (31.3%). HAS reduced the overall OR of renal dysfunction and recurrent ascites.
Conclusions: HAS has shown a reduction in mortality and several complications. However, these benefits were primarily observed in small, low-quality trials, suggesting the need for large, well-designed RCTs before definitive recommendations can be made.
(Copyright © 2026 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.)*